Association for Accessible Medicines v. Becerra

• Court: District Court, E.D. California
• Decided: December 31, 2019
• Docket: 2:19-cv-02281
• Status: Unknown

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 EASTERN DISTRICT OF CALIFORNIA 10 11 ASSOCIATION FOR ACCESSIBLE No. 2:19-cv-02281-TLN-DB MEDICINES, 12 Plaintiff, 13 MEMORANDUM AND ORDER ON v. PLAINTIFF’S MOTION FOR 14 PRELIMINARY INJUNCTION XAVIER BECERRA, in his official 15 capacity as Attorney General of the State of California, 16 Defendant. 17

18 19 This matter is before the Court on Plaintiff Association for Accessible Medicine’s 20 (“Plaintiff” or “AAM”) Motion for Preliminary Injunction requesting the Court enjoin the 21 implementation or enforcement of Assembly Bill 824 (“AB 824”). (ECF No. 10.) Defendant 22 Attorney General Xavier Becerra (“Defendant” or the “State”) filed an opposition on December 23 10, 2019. (ECF No. 24.) Plaintiff filed a reply on December 17, 2019. (ECF No. 27.) The Court 24 also considered Amicus Curiae briefs submitted by various interested parties (ECF Nos. 21, 25), 25 and the Court heard oral argument on December 19, 2020 (See ECF No. 28, hearing minutes). 26 After carefully considering all material presented to the Court and for the reasons set forth below, 27 Plaintiff’s Motion is DENIED. 28 /// 1 I. FACTUAL AND PROCEDURAL BACKGROUND1 2 AB 824 creates a presumption that “reverse payment” settlement agreements regarding 3 patent infringement claims between brand-name and generic pharmaceutical companies are anti- 4 competitive and unlawful. 5 Reverse payment settlements arise primarily — if not exclusively — in the context of 6 pharmaceutical drug regulations and suits brought under the statutory provisions of the Drug 7 Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch- 8 Waxman Act. Under the Hatch-Waxman Act, once a brand-name company has submitted a new 9 prescription drug to the FDA and gained approval to market it, a manufacturer of a generic drug 10 with the same active ingredients that is biologically equivalent to the approved brand-name drug 11 can gain approval to market the generic through an abbreviated FDA process. The New Drug 12 Application (“NDA”) process is long, comprehensive, and expensive whereas the Abbreviated 13 New Drug Application (“ANDA”) process that a generic drug is subjected to is substantially less 14 expensive and requires far less testing. 15 In order to gain approval through the FDA, the generic company must file an ANDA. As 16 part of this application, the generic company must assure the FDA that its drug will not infringe 17 on any patents owned by the brand-name drug company. One way to do so is for the generic 18 company to certify that any listed, relevant patent is invalid or will not be infringed by the 19 manufacture, use, or sale of the generic drug. This is called a Paragraph IV certification. 20 Because filing under Paragraph IV indicates that there are current patents that the generic 21 company asserts are invalid or uninfringed by its product, the Paragraph IV certification is per se 22 a patent infringement and thus the brand-name company can, and often does, bring suit against 23 the generic drug manufacturer. 24 Settlements of the resulting lawsuits sometimes include reverse payments in which the 25 plaintiff, the brand-name drug company, pays the defendant, the infringing generic drug 26 1 The following recitation of facts is derived from Plaintiff’s Complaint (ECF No. 1), as 27 well as the parties’ briefing on the Motion for Preliminary Injunction (ECF Nos. 10, 24, 27). Additionally, the Court gathered general background information from FTC v. Actavis, Inc., 570 28 U.S. 136 (2013). 1 company, a sum of money for the promise that the generic drug company will keeps its drug off 2 the market for an agreed-upon length of time. 3 AB 824 targets these types of settlements. According to the State, AB 824 closes this 4 loophole in the Hatch-Waxman Act and ensures that a brand-name drug company cannot continue 5 to enforce an otherwise weak patent against generics through these reverse payment settlements. 6 AB 824 imposes a presumption that a settlement agreement involving a brand-name 7 company compensating the generic for keeping its drug off the market is anticompetitive under 8 California Antitrust Law. It also levies a civil penalty against any individual who assists in the 9 violation of the section of three times the value received by the individual due to the violation or 10 $20 million, whichever is greater. 11 Plaintiff asserts the following causes of action, all in an attempt to invalidate AB 824: (1) 12 Declaratory/Injunctive Relief — Commerce Clause — Extraterritoriality; (2) 13 Declaratory/Injunctive Relief — Preemption; (3) Declaratory/Injunctive Relief — Excessive 14 Fines Clause; (4) Declaratory/Injunctive Relief — Due Process — Burden Shifting; (5) 42 U.S.C. 15 § 1983 and 42 U.S.C. § 1988. (ECF No. 1 at 30–51.) More specifically, Plaintiff alleges AB 824 16 violates the Dormant Commerce Clause by directly regulating out-of-state conduct; is preempted 17 by federal patent law and the delicate balance between the competing interests of patent 18 protections and anti-trust law struck by the Supreme Court in FTC v. Actavis, Inc., 570 U.S. 136 19 (2013); violates the constitutional prohibition of excessive fines under the Eight Amendment; and 20 violates due process in that it creates a burden shift with no meaningful opportunity for defendant 21 to rebut the presumption applied. Presently before the Court is Plaintiff’s Motion (ECF No. 10) 22 seeking a preliminary injunction prohibiting the enforcement of this law, which would otherwise 23 take effect January 1, 2020. 24 II. STANDARD 25 Injunctive relief is “an extraordinary remedy that may only be awarded upon a clear 26 showing that the plaintiff is entitled to such relief.” Winter v. Natural Res. Def. Council, Inc., 555 27 U.S. 7, 22 (2008) (citing Mazurek v. Armstrong, 520 U.S. 968, 972 (1997) (per curiam)). “The 28 purpose of a preliminary injunction is merely to preserve the relative positions of the parties until 1 a trial on the merits can be held.” Univ. of Tex. v. Camenisch, 451 U.S. 390, 395 (1981); see also 2 Costa Mesa City Emps. Ass’n v. City of Costa Mesa, 209 Cal. App. 4th 298, 305 (2012) (“The 3 purpose of such an order is to preserve the status quo until a final determination following a 4 trial.”); GoTo.com, Inc. v. Walt Disney, Co., 202 F.3d 1199, 1210 (9th Cir. 2000) (“The status quo 5 ante litem refers not simply to any situation before the filing of a lawsuit, but instead to the last 6 uncontested status which preceded the pending controversy.”). 7 “A plaintiff seeking a preliminary injunction must establish [1] that he is likely to succeed 8 on the merits, [2] that he is likely to suffer irreparable harm in the absence of preliminary relief, 9 [3] that the balance of equities tips in his favor, and [4] that an injunction is in the public interest.” 10 Winter, 555 U.S. at 20. A plaintiff must “make a showing on all four prongs” of the Winter test 11 to obtain a preliminary injunction. Alliance for the Wild Rockies v. Cottrell, 632 F.3d 1127, 1135 12 (9th Cir. 2011). In evaluating a plaintiff's motion for preliminary injunction, a district court may 13 weigh the plaintiff's showings on the Winter elements using a sliding-scale approach. Id. A 14 stronger showing on the balance of the hardships may support issuing a preliminary injunction 15 even where the plaintiff shows that there are “serious questions on the merits . . . so long as the 16 plaintiff also shows that there is a likelihood of irreparable injury and that the injunction is in the 17 public interest.” Id. Simply put, a plaintiff must demonstrate, “that [if] serious questions going to 18 the merits were raised [then] the balance of hardships [must] tip[ ] sharply in the plaintiff's favor,” 19 in order to succeed in a request for preliminary injunction. Id. at 1134–35 (emphasis added). 20 III. STANDING 21 Neither party has raised any issues with respect to standing. Nevertheless, “federal courts 22 are required sua sponte to examine jurisdictional issues such as standing.” Chapman v. Pier 1 23 Imports (U.S.) Inc., 631 F.3d 939, 954 (9th Cir. 2011) (quoting Bernhardt v. Cty. of L.A., 279 24 F.3d 862, 868 (9th Cir. 2002)). And “[t]he existence of Article III standing is not subject to 25 waiver.” Chapman, 631 F.3d at 954. To establish Article III standing, a plaintiff must have “(1) 26 suffered an injury in fact, (2) that is fairly traceable to the challenged conduct of the defendant, 27 and (3) that is likely to be redressed by a favorable judicial decision.” Spokeo, Inc. v. Robins, 136 28 S. Ct. 1540, 1547 (2016). 1 “[A]n association has standing to bring suit on behalf of its members when: (a) its 2 members would otherwise have standing to sue in their own right; (b) the interests it seeks to 3 protect are germane to the organization's purpose; and (c) neither the claim asserted nor the relief 4 requested requires the participation of individual members in the lawsuit.” Hunt v. Washington 5 State Apple Advert. Comm'n, 432 U.S. 333, 343 (1977). Further, “[w]hether an association has 6 standing to invoke the court's remedial powers on behalf of its members depends in substantial 7 measure on the nature of the relief sought. If in a proper case the association seeks a declaration, 8 injunction, or some other form of prospective relief, it can reasonably be supposed that the 9 remedy, if granted, will inure to the benefit of those members of the association actually injured. 10 Indeed, in all cases in which we have expressly recognized standing in associations to represent 11 their members, the relief sought has been of this kind.” Id. (citing Warth v. Seldin, 422 U.S. 490, 12 515 (1975)). 13 Here, Plaintiff is a nonprofit, voluntary association representing the leading manufacturers 14 and distributors of generic and biosimilar medicines, manufacturers and distributors of bulk active 15 pharmaceutical ingredients, and suppliers of other goods and services to the generic and 16 biosimilar pharmaceutical industry. (ECF No. 1 ¶ 12.) As clarified at oral argument, Plaintiff 17 asserts representational standing on behalf of its members, alleging that its members have many 18 ongoing cases involving patent infringement, and other members are currently developing 19 generics and/or contemplating filing ANDAs. (ECF No. 1 ¶¶ 14–15.) Plaintiff seeks injunctive 20 relief while claiming its members will be injured by the implementation of AB 824. (ECF No. 1 21 ¶ 16.) The Court finds Plaintiff has sufficiently alleged the elements of representational standing 22 to bring the instant motion for preliminary injunction. 23 IV. REQUEST FOR JUDICIAL NOTICE 24 At the outset, Defendant requests the Court take judicial notice of five documents 25 pursuant to Federal Rule of Evidence 201: (1) Assembly Committee on Health AB 824 Bill 26 Analysis (March 26, 2019), attached to Defendant’s Request for Judicial Notice (“RJN,” ECF No. 27 24-1) as Exhibit A; (2) Assembly Floor Analysis of AB 824 (September 4, 2019), attached to 28 RJN as Exhibit B; (3) Letters of Support for AB 824, attached to RJN as Exhibit C; (4) Table 8: 1 Total All Payers State Estimates by State of Residence (1991–2014) — Drugs and Other Non- 2 durable Products (Millions of Dollars), attached to RJN as Exhibit D; and (5) Pay-for-Delay: 3 How Drug Company Pay-Offs Cost Consumers Billions, FTC Staff Study (Jan. 2010), attached to 4 RJN as Exhibit E. The State contends judicial notice of Exhibits A, B, and C is appropriate 5 because they are documents that are part of the legislative history of AB 824. The State asserts 6 Exhibits D and E are appropriate for judicial notice because the documents were “administered by 7 or filed with an administrative agency that is not subject to reasonable dispute and is ‘capable of 8 accurate and ready determination by resort to sources whose accuracy cannot reasonably be 9 questioned.’” (ECF No. 24-1 at 2, quoting Fed. R. Evid. 201.) Plaintiff does not oppose the 10 State’s request, and the Court finds all five documents are appropriate for judicial notice. 11 Exhibits A, B, and C are part of the legislative history of AB 824, and courts routinely 12 take judicial notice of legislative history documents. Anderson v. Holder, 673 F.3d 1089, 1094 13 n.1 (9th Cir. 2012) (citing Chaker v. Crogan, 428 F.3d 1215, 1223 n. 8 (9th Cir.2005)) 14 (“Legislative history is properly a subject of judicial notice.”); Korematsu v. United States, 584 F. 15 Supp. 1406, 1414 (N.D. Cal. 1984) (citing Territory of Alaska v. American Can Co., 358 U.S. 16 224, 227 (1959)) (“[C]ourts frequently take judicial notice of legislative history, including 17 committee reports.”). Similarly, a court “may take judicial notice of ‘records and reports of 18 administrative bodies.’” Anderson, 673 F.3d at 1094 (citing Mack v. South Bay Beer Distributors, 19 Inc., 798 F.2d 1279, 1282 (9th Cir.1986)). Exhibit D — a summary table from the Centers for 20 Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group, 21 available on CMS.gov; and Exhibit E — an “FTC Staff Study” available on ftc.gov, are such 22 reports. 23 Defendant’s unopposed Request for Judicial Notice (ECF No. 24) is therefore GRANTED 24 and the Court hereby judicially notices Exhibits A through E attached thereto. 25 V. PRELIMINARY INJUNCTION ANALYSIS 26 Plaintiff’s Complaint asserts five causes of action, the first four of which encompass the 27 present request for preliminary injunction. As explained below, and primarily due to the nature of 28 Plaintiff’s pre-enforcement attack on AB 824, the Court finds Plaintiff has failed to establish a 1 likelihood of success on the merits of its claims, nor has it raised serious questions going to those 2 merits. Moreover, the Court finds that absent a constitutional violation Plaintiff has failed to 3 establish an irreparable harm that is both likely and — at this time — imminent. And lastly, even 4 if the Court were to find serious questions going to the merits of Plaintiff’s claims, the question of 5 balance of harms and public interest are too speculative at this point for the Court to find that 6 either factor favors Plaintiff, sharply or otherwise. 7 A. Likelihood of Success on the Merits 8 In an attempt to enjoin enforcement of AB 824 before it takes effect on January 1, 2010, 9 Plaintiff asserts the bill: (1) violates the Dorman Commerce Clause; (2) is preempted; (3) violates 10 the Excessive Fines Clause of the Eighth Amendment; and (4) violates the Due Process Clause. 11 Plaintiff’s attack on AB 824 is in part both facial and as-applied. As discussed below, Plaintiff 12 has failed to establish a likelihood of success on the merits of any of these claims and as a result, 13 the Court finds a preliminary injunction is inappropriate at this time. 14 1. Dormant Commerce Clause 15 In its moving papers, Plaintiff indicates AB 824 — because it is not limited to settlement 16 agreements entered into in California or between California entities — directly regulates out of 17 state commerce and is therefore a per se violation of the Dormant Commerce Clause. 18 Interpreting this as a facial attack on AB 824, the State argues that because AB 824 can 19 conceivably be applied to settlement agreements contained within California, it has at least one 20 constitutional application and so Plaintiff’s facial attack fails. 21 Indeed, a facial challenge is “the most difficult challenge to mount successfully, since the 22 challenger must establish that no set of circumstances exists under which the Act would be valid. 23 The fact that [an] Act might operate unconstitutionally under some conceivable set of 24 circumstances is insufficient to render it wholly invalid, since we have not recognized an 25 ‘overbreadth’ doctrine outside the limited context of the First Amendment.” United States v. 26 Salerno, 481 U.S. 739, 745 (1987). Facial challenges are disfavored because they often require 27 the court to make constitutional determinations based on hypothetical situations. Washington 28 State Grange v. Washington State Republican Party, 552 U.S. 442, 449–51 (2008) (“Claims of 1 facial invalidity often rest on speculation. As a consequence, they raise the risk of premature 2 interpretation of statutes on the basis of factually barebones records.” (internal citation omitted)). 3 Here, Plaintiff poses the hypothetical situation of non-California entities entering into a settlement 4 agreement outside of California, and then asks the Court to assume that California would seek to 5 enforce AB 824 against these hypothetical parties. But invalidating or even preliminarily 6 enjoining the law on this basis would force the Court to not only assume the Attorney General 7 will apply the law unconstitutionally, but also to make a constitutional determination before it is 8 necessary to do so. Washington State Grange v. Washington State Republican Party, 552 U.S. 9 442, 449–51 (2008) (“Facial challenges also run contrary to the fundamental principle of judicial 10 restraint that courts should neither anticipate a question of constitutional law in advance of the 11 necessity of deciding it nor formulate a rule of constitutional law broader than is required by the 12 precise facts to which it is to be applied.” (internal quotes and citations omitted)). Such a facial 13 attack therefore fails where, as here, a set of circumstances exists under which AB 824 will be 14 valid. 15 Plaintiff seems to concede this point, clarifying its position in its reply brief and in oral 16 argument that it is not raising a facial attack against AB 824, but an as-applied attack. (ECF No. 17 27 at 7.) An as applied challenge looks at a specific plaintiff and set of circumstances and 18 determines if the law is constitutional as applied to that set of circumstances. Wal-Mart Stores, 19 Inc. v. City of Turlock, 483 F. Supp. 2d 987, 996–97 (E.D. Cal. 2006) (citing 16 C.J.S. 20 Constitutional Law § 187) (“When faced with a claim that application of a statute renders it 21 unconstitutional, a court must analyze the statute as applied to the particular case, i.e., how it 22 operates in practice against the particular litigant and under the facts of the instant case, not 23 hypothetical facts in other situations”). In other words, Plaintiff claims AB 824 “as applied to 24 settlement agreements that were not negotiated, completed, or entered in California,” violates the 25 Dormant Commerce Clause. (ECF No. 27 at 7.) Indeed, if the Attorney General were to enforce 26 the terms of AB 824 against two out of state parties that entered into a settlement agreement 27 outside of California, having nothing to do with California, such conduct would likely violate the 28 Dormant Commerce Clause. In this case, however, AB 824 has yet to take effect. As a result, the 1 Court cannot consider the law as it has been applied to a particular agreement or party. Rather, 2 Plaintiff raises a “paradigmatic as-applied challenge” to AB 824, urging the Court to find that 3 “the application of the statute to a specific factual circumstance” is in violation of the Dormant 4 Commerce Clause. (Id. (citing Hoye v. City of Oakland, 653 F.3d 835, 857 (9th Cir. 2011)).) 5 Plaintiff asserts the fact that AB 824 hasn’t been enforced yet is not detrimental to its challenge, 6 citing case law in support of its position that a pre-enforcement as-applied challenge is ripe “so 7 long as [it] present[s] a ‘discrete and well-defined’ application of the challenged law that is ‘likely 8 to occur.’” (Id. (citing Gonzales v. Carhart, 550 U.S. 124, 167 (2007)).) 9 In oral argument, the State did not blanketly refute Plaintiff’s attempt to raise a pre- 10 enforcement as-applied attack on AB 824, but rather highlighted Plaintiff’s failure to meet the 11 standard required under such an attack. Stressing that neither Hoye nor Gonzales supports 12 Plaintiff’s position, the State in oral argument contended that a pre-enforcement as-applied attack 13 requires a showing of three things, none of which Plaintiff has established: (1) a concrete plan to 14 violate the law; (2) a communicated threat of prosecution; and (3) a history of past prosecution or 15 enforcement of the challenged law. 16 Whether Plaintiff’s Dormant Commerce Clause claim as asserted is likely to succeed 17 depends first on whether that claim is ripe. While allowing pre-enforcement, as-applied 18 challenges, Gonzalez does not allow for Plaintiff’s broad request. In Gonzalez, the Supreme 19 Court denied a request to find a partial-birth abortion ban facially unconstitutional. Instead, it 20 concluded that an as-applied challenge was the “proper means to consider exceptions” to the law 21 because in such an as-applied challenge “it can be shown that in discrete and well-defined 22 instances a particular condition has or is likely to occur in which the prohibited act must be used.” 23 Id. at 167. In the first instance, it is not clear to the Court that Gonzalez’ standard applies outside 24 of the narrow context of abortion law. Moreover, Gonzalez says nothing about the specificity 25 needed to bring a pre-enforcement as-applied challenge but instead reinforces the general 26 proposition that the court should not reach findings of unconstitutionality based on hypotheticals.2 27 2 Neither does Hoye v. City of Oakland, 653 F.3d 835 (9th Cir. 2011) stand for the broad 28 proposition that a party can successfully bring an as-applied pre-enforcement challenge to a 1 As the State articulated in oral argument, the constitutional test for ripeness consists of 2 three parts: (1) a concrete plan to violate the law; (2) a communicated threat of prosecution; and 3 (3) a history of past prosecution or enforcement of the challenged law. See, e.g., Clark v. City of 4 Seattle, 899 F.3d 802 (9th Cir. 2018) (“Where a plaintiff intends to challenge a statute prior to its 5 enforcement, generalized threats of prosecution do not confer constitutional ripeness. Rather, 6 there must be a genuine threat of imminent prosecution. To determine whether a genuine threat 7 of imminent prosecution exists, we use three factors . . . .” (citations and internal quotation marks 8 omitted); Maldonado v. Morales, 556 F.3d 1037, 1044 (9th Cir. 2009). Moreover, the “prudential 9 inquiry” concerning ripeness weighs “the fitness of the issue for judicial decision and the 10 hardship to the parties of withholding court consideration.” Maldonado, 556 F.3d at 1044 11 (quoting Abbott Labs. v. Gardner, 387 U.S. 136, 148 (1967), overruled on other grounds by 12 Califano v. Sanders, 430 U.S. 99 (1977)). The former question includes consideration of whether 13 the issue is purely legal or one that requires factual development. See San Diego Gun Rights 14 Committee v. Reno, 98 F.3d 1121 (9th Cir. 1996) (not ripe because “the issues in the instant pre- 15 enforcement challenge are not purely legal. A concrete factual situation is necessary to delineate 16 the boundaries of what conduct the government may or may not regulate without running afoul of 17 the Commerce Clause.”) Plaintiff has made no attempt to establish these three constitutional 18 elements nor to discuss the prudential concerns. 19 Even so, applying either Clarks three-pronged test or the more general rule as stated in 20 Gonzalez to the instant case, Plaintiff has not established a likelihood of success on the merits of 21 its pre-enforcement as-applied challenge because it has not established that the issue is ripe for 22 review. Specifically, Plaintiff has not sufficiently shown that AB 824 is likely to be enforced in 23 an unconstitutional manner, nor has Plaintiff stated neither a plan to violate the law or a specific 24 threat that the law will be enforced in the manner they fear. Plaintiff relies heavily on the 25

26 statute under all circumstances. Rather, aside from articulating that a paradigmatic as-applied approach can be appropriate at least in the context of First Amendment jurisprudence, Hoye offers 27 little support for Plaintiff’s position and only further confirms that courts “decline[] to entertain as-applied challenges that would require [them] to speculate as to prospective facts.” Id. at 859. 28 1 declarations it submitted in support of its motion for preliminary injunction. (See ECF Nos. 10- 2 2–10-7.) Plaintiff’s briefs make these declarations out to be bold statements that should AB 824 3 go into effect, the subject companies will be forced to make drastic changes to their business 4 practices. However, none of the declarations state an intent to violate AB 824, and none lay out a 5 specific circumstance in which AB 824 will be applied. Instead, the declarants make generalized 6 statements that there are many lawsuits arising from ANDA Paragraph IV applications, that many 7 such lawsuits have settled (it is not clear how many settled with reverse payments), and that AB 8 824 may have some impact on these cases. The declarants claim they will likely be forced to 9 litigate pending patent-infringement lawsuits to judgment out of fear of AB 824’s penalties, even 10 if a procompetitive settlement could be reached. Declarants also claim they may keep the new 11 generics they are currently developing off the market, or will be required to reevaluate their plans, 12 rather than risk the cost of litigation or face AB 824 penalties. But no declarant claims its 13 company has a concrete plan to violate the terms of AB 824. (See id.) Had Plaintiff submitted 14 evidence of a currently pending reverse payment settlement negotiation in which the parties 15 would not settle as a result of AB 824 or feared prosecution under AB 824, then this case might 16 be ripe for a pre-enforcement, as-applied challenge. However, that is not the case. Rather, and 17 more to the point regarding prudential ripeness, it is clear to the Court that this is not a purely 18 legal issue, and that additional facts are necessary to address the Commerce Clause question. 19 Because the Court finds Plaintiff’s pre-enforcement as-applied claim under the Dormant 20 Commerce Clause is not ripe for review, the Court finds Plaintiff has not established a likelihood 21 of success on the merits of its claim, nor has Plaintiff raised serious questions going to the merits, 22 and so a preliminary injunction shall not issue on these grounds at this time.3 Even if Plaintiff 23 3 Plaintiff’s pre-enforcement as-applied challenge is also problematic because it may be 24 construed as an attempt to extend a facial overbreadth challenge outside the First Amendment context. In theory, Plaintiff claims that the language of the law in question is overbroad because 25 it may allow the government to enforce it unconstitutionally. See, e.g., Sabri v. U.S., 541 U.S. 600, 609 (2004) (“It would have been correspondingly clear that if Sabri was making any 26 substantive constitutional claim, it had to be seen as an overbreadth challenge; the most he could 27 say was that the statute could not be enforced against him, because it could not be enforced against someone else whose behavior would be outside the scope of Congress's Article I authority 28 to legislate.”). But under Plaintiff’s logic, any law regarding commerce passed by the California 1 had raised serious questions as to the merits of its Dormant Commerce Clause claim, the balance 2 of hardships does not tip significantly in Plaintiff’s favor, as discussed below, such that a 3 preliminary injunction should be granted. 4 2. Preemption 5 Plaintiff makes two primary arguments concerning preemption. First, Plaintiff asserts AB 6 824 conflicts with the objectives of federal patent law, and specifically the Hatch-Waxman Act. 7 And second, Plaintiff argues AB 824 is directly preempted by both the Patent Act and by the 8 delicate balance struck between antitrust law and patent law, as discussed by the Supreme Court 9 in FTC v Actavis, 570 U.S. 136 (2013). For its part, the State asserts that AB 824 does not 10 conflict with federal patent law and notes that Plaintiff does not identify “a specific patent 11 provision with which AB 824 conflicts.” (ECF No. 24 at 7.) The State also contends that AB 12 824 does not conflict with the Hatch-Waxman Act because it will further the goals of the Act, not 13 frustrate them as Plaintiff claims. And finally, the State argues that Actavis does not preempt AB 14 824 because it weighed in on the interaction between federal, as opposed to state, antitrust law 15 and patent law and established only that patent settlements were not per se exempt from antitrust 16 liability. 17 Plaintiff indeed has not pointed to any provision of the Patent Act that conflicts with AB 18 824 except to assert in oral argument that federal patent law is entitled to field preemption and 19 states cannot create their own patent-like protections. While this assertion is correct, it does not 20 settle the question of preemption presented to this Court. “[S]tate law is preempted when it enters 21 ‘a field of regulation which the patent laws have reserved to Congress.’ Where state law offers 22 ‘patent-like protection for ideas deemed unprotected under the present federal scheme, [state law] 23 conflicts with the strong federal policy favoring free competition in ideas.’” Summit Mach. Tool 24 Mfg. Corp. v. Victor CNC Sys., Inc., 7 F.3d 1434, 1439 (9th Cir. 1993) (citing Bonito Boats, Inc. 25

legislature would have to include language specifically limiting its application to within 26 California. That simply cannot be the case, and Plaintiff cites to no authority indicating 27 otherwise. Moreover, Sabri cautioned against overbreadth challenges applied outside the scope of the First Amendment and the Supreme Court has regularly declined to extend such an analysis 28 to other constitutional challenges. Id. at 609–610. 1 v. Thunder Craft Boats, Inc., 489 U.S. 141, 167 (1989)). But AB 824 is not offering patent-like 2 protection; instead it is imposing a presumption of anti-competitiveness on certain types of patent 3 settlements. A state law claim can survive federal patent law preemption so long as the state 4 claim “contains an element not shared by the federal law; an element which changes the nature of 5 the action so that it is qualitatively different from a copyright [or patent] infringement claim.” 6 Summit Mach. Tool Mfg. Corp. v. Victor CNC Sys., Inc., 7 F.3d 1434, 1439–40 (9th Cir. 1993) 7 (internal quotation omitted, brackets in original) (considering state law misappropriation claim in 8 light of federal patent laws). AB 824 does not require a court to determine the validity or 9 invalidity of a patent. Instead, it is focused on the payment of a “thing of value” to the generic 10 drug company and attaches a presumption that such a transfer serves anti-competitive purposes. 11 Because AB 824 does not require determination of the validity of a patent and does not create 12 patent-like protections, it does not conflict with federal patent law and is therefore not preempted 13 under this analysis. 14 Plaintiff’s next assertion that AB 824 conflicts with, and is therefore preempted by, the 15 Hatch-Waxman Act is predicated on Plaintiff’s claim that the ultimate effect of AB 824 will be to 16 stifle the creation, production, and entry onto the market of cheaper generic medications. The 17 State, by contrast, argues that the intent of AB 824 is to ensure that generic drugs are not kept off 18 the market by the practice of reverse payment settlements and banning these settlements will 19 ensure generics enter the market sooner, ultimately decreasing drug prices and protecting the 20 public’s access to affordable medicine. The parties agree that the intent of the Hatch-Waxman 21 Act was to create a pathway for generic medications to enter the market faster and to lower 22 prescription drug prices as a result. The argument of each party turns on how exactly AB 824 23 will impact these goals. Because AB 824 has not been enacted, nor has any other similar law 24 been enacted in another state, it is impossible to know if this law will have its intended effect, or 25 as Plaintiff argues, will backfire, causing generic drug companies to cease filing ANDA 26 applications and challenging patents held by brand-name drug companies. The Court is not in a 27 position to predict the future impacts of AB 824 before it is enacted and enforced. At this time, it 28 is too speculative for the Court to find one way or another that AB 824 will frustrate or further the 1 aims of the Hatch-Waxman Act. As such, Plaintiff cannot show a likelihood of success on the 2 merits of its conflict preemption claim. 3 Finally, Plaintiff argues Actavis “went out of its way to protect” (ECF No 10-1 at 22) the 4 delicate balance Congress struck between patent law and antitrust law. Plaintiff contends AB 824 5 disrupts this balance and is therefore preempted by Actavis. In support of this assertion, Plaintiff 6 cites Connell Const. Co. v. Plumbers & Steamfitters Local Union No. 100, 421 U.S. 616 (1975), a 7 case in which the Supreme Court found that “[b]ecause employee organization is central to 8 federal labor policy and regulation of organizational procedures is comprehensive, federal law 9 does not admit the use of state antitrust law to regulate union activity that is closely related to 10 organizational goals.” In Connell Construction, the Supreme Court limited the application of 11 state antitrust law to federal labor laws. In Actavis, by contrast, the Supreme Court opened 12 reverse payment patent settlements to antitrust scrutiny rather than limiting the application of 13 antitrust law to patent settlements. Therefore, Connell Construction is inapposite. 14 Actavis’ holding opens patent settlements to antitrust scrutiny by overturning previous 15 circuit court precedent that reverse payment settlements do not present antitrust concerns “so long 16 as its anticompetitive effects fall within the scope of the exclusionary potential of the patent.” 17 570 U.S. at 141 (internal quotes omitted). Instead of following the circuit analysis, Actavis 18 applied antitrust law to reverse payment settlements and found that such settlements may violate 19 federal antitrust laws. Actavis’ analysis is based not on a presumption of validity of the 20 underlying patent, but rather on the balance between the anti- and pro-competitive impacts of the 21 settlement agreement. 22 Plaintiff notes the California Supreme Court acknowledged that the “United States 23 Supreme Court is the final arbiter of questions of patent law and the extent to which 24 interpretations of antitrust law — whether state or federal — must accommodate patent law's 25 requirements . . . .” In re Cipro Cases I & II, 61 Cal. 4th 116, 142 (2015). Plaintiff posits that the 26 finding in Actavis therefore precludes California from imposing its own antitrust laws on reverse 27 payment patent settlements. However, the California Supreme Court determined that “the lesson 28 of Actavis is that nothing in the patent laws or the Hatch–Waxman Act dictates such a special 1 rule; that a settlement resolves a patent dispute does not immunize the agreement from antitrust 2 attack;” and that if federal antitrust law can weigh the pro- and anti-competitive effects of a patent 3 settlement without “offense to patent law, then so too can the state antitrust law.” In re Cipro 4 Cases I & II, 61 Cal. 4th at 161. This Court agrees with the California Supreme Court. The 5 holding in Actavis allows the enforcement of antitrust law on patent settlements rather than 6 foreclosing such enforcement. 7 Plaintiff argues that because Actavis applied a rule of reason test and declined to follow a 8 quick look approach or rely on a presumption, California may not create its own presumption 9 when applying its antitrust law to patent settlements. However, there is no such limitation 10 presented in Actavis and, as the California Supreme Court points out, “Actavis is not dispositive 11 on matters of state law . . . [i]nterpretations of federal antitrust law are at most instructive, not 12 conclusive, when construing the Cartwright Act, given that the Cartwright Act was modeled not 13 on federal antitrust statutes but instead on statutes enacted by California's sister states around the 14 turn of the 20th century.” In re Cipro Cases I & II, 61 Cal. 4th at 142. This Court agrees that 15 Actavis turns on questions of antitrust law, not patent law, and federal antitrust law does not 16 preempt state antitrust law. California v. ARC Am. Corp., 490 U.S. 93, 101–02 (1989) 17 (“Congress has not pre-empted the field of antitrust law . . . Congress intended the federal 18 antitrust laws to supplement, not displace, state antitrust remedies.”). Therefore, Actavis does not 19 preempt AB 824, nor does it prevent California’s imposition of a law establishing a presumption 20 regarding the anticompetitive nature of reverse payment settlements under its own antitrust 21 statutes. 22 Further, while Actavis applies the rule of reason to the analysis of reverse payment 23 settlements under federal antitrust law, it does not establish exactly how and when this test should 24 be applied. Instead, the Court in Actavis explicitly leaves the question of how to apply the rule it 25 articulated to the lower courts. “As in other areas of law, trial courts can structure antitrust 26 litigation so as to avoid, on the one hand, the use of antitrust theories too abbreviated to permit 27 proper analysis, and, on the other, consideration of every possible fact or theory irrespective of 28 the minimal light it may shed on the basic question — that of the presence of significant 1 unjustified anticompetitive consequences. We therefore leave to the lower courts the structuring 2 of the present rule-of-reason antitrust litigation.” 570 U.S. at 159–60. 3 Plaintiff’s arguments that AB 824 is preempted by federal law are therefore not likely to 4 succeed. As a result, Plaintiff cannot show that there is a likelihood of success on the merits. 5 Further, even if Plaintiff had raised serious questions as to the merits of the preemption question, 6 the balance of hardships does not tip significantly in Plaintiff’s favor, as discussed below, such 7 that a preliminary injunction should be granted. 8 3. Excessive Fines 9 In terms of a penalty, AB 824 imposes a fine against any individual who assists in what is 10 deemed to be a violation of the bill of three times the value received by the individual due to the 11 violation or $20 million, whichever is greater. By the terms of the bill, this minimum of $20 12 million applies to any individual who assists in the party’s violation even if that person gained 13 nothing of value as a result of the violation. Presumably, such a penalty could be levied against a 14 junior associate or legal secretary working at the law firm representing one of the settling parties. 15 Plaintiff raises two arguments that AB 824 imposes excessive fines: (1) that the upper 16 threshold of three times the value received is excessive in relation to the purported 17 anticompetitive harms of any violative settlement agreement; and (2) that a minimum fine of $20 18 million is excessive as it applies to individuals, as opposed to parties. For its part, the State 19 argues, (1) Plaintiff’s claim is not ripe for determination because such a claim is dependent on a 20 number of factual inquiries not presently before the Court; (2) the Court should defer to the State 21 in setting penalties or fixing fines unless they are so grossly excessive as to amount to a due 22 process violation;4 and (3) because Plaintiff is bringing a facial attack on AB 824, its claim can 23 only succeed if it shows no set of circumstances exist under which the Act would be valid, which 24 it cannot do.

25 4 The Court acknowledges Plaintiff’s reference to the recent case of Timbs v. Indiana, 139 S. Ct. 682, 687–89 (2019), which holds the Excessive Fines Clause is fully incorporated against 26 the states. The Court need not and does not determine whether such incorporation revokes the 27 deference otherwise afforded to the State to set penalties and fines. Because the Court finds Plaintiff’s Excessive Fines claim is unripe, it need not consider the State’s argument for 28 deference. 1 The parties agree that the Eighth Amendment prohibits states from imposing “excessive 2 fines” and has been applied where the fine is imposed, in whole or in part, as punishment for an 3 offense. The parties also do not dispute that the fine imposed under AB 824 is intended as a 4 penalty and further agree that a fine is considered excessive if it is disproportionate to the gravity 5 of the offense. In the Ninth Circuit, courts consider four factors in determining whether a penalty 6 is grossly disproportionate to the offense: (1) the nature and extent of the violation; (2) whether 7 the violation was related to other illegal activities; (3) other penalties that may be imposed for the 8 violation; and (4) the extent of the harm caused. (ECF No. 10 at 28; ECF No. 24 at 12; see 9 United States v. $132,245.00 in U.S. Currency, 764 F.3d 1055, 1058 (9th Cir. 2014)). 10 It is not entirely clear whether Plaintiff intends to raise a facial or as-applied attack against 11 the penalty portion of AB 824. At least with respect to Plaintiff’s claim that the upper threshold 12 is excessive in relation to the purported anticompetitive harms of any violative settlement 13 agreement, Plaintiff’s attack — seeking to invalidate the law (or at least enjoin the penalty 14 provision) as applied to any defendant — is necessarily a facial one. See Hoye, 653 F.3d at 857 15 (“Because the difference between an as-applied and a facial challenge lies only in whether all or 16 only some of the statute's subrules (or fact-specific applications) are being challenged, the 17 substantive legal tests used in the two challenges are ‘invariant.’”) As discussed above, a facial 18 attack of a law is exceedingly difficult to raise successfully. “[T]he Court’s analysis of Plaintiffs’ 19 facial excessive fines claims asks whether parts of the penalty structure are always grossly 20 disproportional, or if there are circumstances where the penalties would be valid.” In re Toll 21 Roads Litig., No. SACV1600262AGJCGX, 2018 WL 4945314, at *2 (C.D. Cal. July 31, 2018) 22 (citing United States v. Bajakajian, 524 U.S. 321, 336 (1998)); United States v. Salerno, 481 U.S. 23 739, 745 (1987). Certainly, the Court can fathom a set of circumstances in the context of massive 24 pharmaceutical settlements under which the imposition of three times the value received due to 25 the violation or $20 million, whichever is greater, might be appropriate. At the most general 26 level, then, Plaintiff’s facial attack again fails. 27 Moreover, and as the parties agree, in evaluating a claim under the Excessive Fines 28 Clause, “the standard of gross disproportionality” requires a court to “compare the amount of the 1 forfeiture to the gravity of the [ ] offense. If the amount of the forfeiture is grossly 2 disproportional to the gravity of the defendant's offense, it is unconstitutional.” Bajakajian, 524 3 U.S. at 336-37. In the Ninth Circuit, this typically requires courts to consider the four factors 4 articulated above: (1) the nature and extent of the violation; (2) whether the violation was related 5 to other illegal activities; (3) other penalties that may be imposed for the violation; and (4) the 6 extent of the harm caused. See United States v. $132,245.00 in U.S. Currency, 764 F.3d 1055, 7 1058 (9th Cir. 2014). Each of these four factors — perhaps with the exception of the third — are 8 all but impossible to assess in the abstract, highlighting the difficulty of a pre-enforcement attack 9 based on the Excessive Fines Clause. As one district court noted, “[t]he first factor requires 10 review of the circumstances of the offense ‘in great detail.’” Crawford v. United States Dep't of 11 the Treasury, No. 3:15-CV-250, 2015 WL 5697552, at *14–15 (S.D. Ohio Sept. 29, 2015), (citing 12 Solem v. Helm, 463 U.S. 277, 290–91 (1983) (Cruel and Unusual Punishments Clause analysis)). 13 “In this case, there are no circumstances to review, because no . . . penalty has been imposed. A 14 fact-specific determination of excessiveness is impossible where any wrongful conduct is 15 hypothetical.” Id. The same is true here. 16 In other words, without examining the factual underpinnings of an actual violation the 17 Court can hardly speculate as to the nature and extent of the violation, whether the violation is 18 related to other illegal activities (perhaps unlikely in this scenario, but not impossible), and the 19 extent of the harm caused, if any, as it is yet unknown. Plaintiff’s arguments to the contrary hinge 20 on its position that “run-of-the-mill patent settlements” are not at all harmful, and thus such a 21 pricey penalty is excessive. (See ECF No. 10 at 28–29.) But it is not so clear to the Court that the 22 settlements impacted by AB 824 will be “run-of-the-mill.” Quite clearly, the State’s position is 23 that AB 824’s goal is to effect only those settlements that are ultimately harming consumers. 24 Without a factual underpinning by which to assess a violation, it is impossible to know if the 25 upper threshold imposed is excessive. Put simply, the Court is not willing at this point to find the 26 upper threshold of AB 824’s penalty provision is grossly disproportional to the gravity of every 27 conceivable violation of the statute. The Court therefore agrees with the State that Plaintiff’s 28 Excessive Fines claim is not ripe for adjudication as it pertains to Plaintiff’s attack of the upper 1 limit imposed under the statute, and Plaintiff has therefore failed to establish a likelihood of 2 success on the merits of this claim. 3 With respect to the $20 million minimum, Plaintiff attempts to clarify in reply that 4 “[c]hallenges to limitations that appear on the face of state laws are ripe the moment the 5 challenged law is enacted,” and further that its “principal Excessive Fines claim is that $20 6 million is excessive as applied to an individual under any scenario.” (ECF No. 27 at 12, 7 emphasis in original.) Because Plaintiff seeks to invalidate or enjoin the penalty provision of AB 8 824 as it might be applied to individuals only, the attack is necessarily an as-applied pre- 9 enforcement attack. 10 Plaintiff fails to cite to any authority establishing that an as-applied pre-enforcement claim 11 is cognizable under the Excessive Fines Clause. But assuming it is, the Court must nevertheless 12 apply the three-part test articulated above with respect to pre-enforcement challenges generally. 13 Specifically, in order to successfully establish that the claim is ripe for review, Plaintiff must 14 show: (1) a concrete plan to violate the law; (2) a communicated threat of prosecution; and (3) a 15 history of past prosecution or enforcement of the challenged law. As discussed above with 16 respect to Plaintiff’s claim under the Dormant Commerce Clause, Plaintiff does not sufficiently 17 meet this standard. Even more so with respect to Plaintiff’s “as-applied to individuals” claim, 18 Plaintiff has made no attempt to proffer evidence that a single individual intends to violate AB 19 824, nor that the State has communicated a threat of levying a $20 million fine against, for 20 example, a junior associate at a law firm who took notes during settlement negotiations. Further, 21 the prudential inquiry leads the Court to find the claim is unripe as it requires factual 22 development. As a result, the Court finds Plaintiff’s pre-enforcement as-applied to individuals 23 attack is not yet ripe, and Plaintiff therefore fails to establish a likelihood of success on the merits 24 of the claim. 25 Lastly, regardless of whether Plaintiff’s Excessive Fines claim is intended as a facial or 26 as-applied attack on the provision as it applies to individuals, any Excessive Fines claim requires 27 a court to consider the four factors articulated above to determine if the fine is disproportionate to 28 the gravity of the offense. Again, those factors are: (1) the nature and extent of the violation; (2) 1 whether the violation was related to other illegal activities; (3) other penalties that may be 2 imposed for the violation; and (4) the extent of the harm caused. See United States v. 3 $132,245.00 in U.S. Currency, 764 F.3d 1055, 1058 (9th Cir. 2014); see also Hoye, 653 F.3d at 4 857 (“Because the difference between an as-applied and a facial challenge lies only in whether all 5 or only some of the statute's subrules (or fact-specific applications) are being challenged, the 6 substantive legal tests used in the two challenges are ‘invariant.’”) In the context of the $20 7 million fine as applied to individuals, Plaintiff comes closer to establishing possible success on 8 this part of the inquiry. To be sure, the Court is troubled that a law firm’s junior associate could 9 theoretically face a $20 million fine for her participation in negotiating a settlement agreement 10 that violates AB 824. But given the posture of this case, the Court cannot say Plaintiff has 11 established a likelihood of success, or even raised serious questions going to the merits of its 12 claim. As explained above, the analysis required to find an Excessive Fines Clause violation is 13 fact-specific. Even narrowing the challenge to the statute as it applies to individuals, the Court 14 cannot analyze the circumstances surrounding a violation before any violation occurs. Indeed, if 15 a $20 million fine is levied against an individual in a case in which the four factors articulated 16 above indicate such a fine is excessive, that individual may apply for a temporary restraining 17 order or injunction and seek to invalidate the law as it is applied unconstitutionally to the 18 individual. Absent those facts, the relief requested is premature. For those reasons, the Court 19 finds Plaintiff has failed to establish a likelihood of success on the merits of its Excessive Fines 20 claim. Further, even if Plaintiff had raised serious questions as to the merits of the claim, the 21 balance of hardships does not tip significantly in Plaintiff’s favor, as discussed below, such that a 22 preliminary injunction should be granted. 23 4. Due Process 24 Finally, Plaintiff argues AB 824 violates due process because (1) it unfairly shifts the 25 burden to the defendant to prove procompetitive effects; (2) the defendant’s opportunity to rebut 26 the presumptions imposed are meaningless because the statute presumes anticompetitive effects; 27 and (3) relatedly, a manufacturer will not be able to prove an agreement has had procompetitive 28 effects, even if that agreement will generate such effects over time. (ECF No. 10 at 30–31.) In 1 opposition, the State argues: (1) the State has the authority to regulate legal procedure, including 2 establishing a burden; (2) AB 824 expressly provides parties a meaningful opportunity to 3 disprove liability once the burden is appropriately shifted; and (3) Plaintiff’s position that the 4 presumptions set forth in AB 824 represent a stark departure from established law is unsupported. 5 (ECF No. 24 at 24–25.) In reply, Plaintiff seems to concede that a burden shift in and of itself is 6 not violative of due process, clarifying that AB 824 is unconstitutional “because it shifts the 7 burden of persuasion to the defendant and also imposes a presumption of guilt while making it 8 effectively impossible to rebut that presumption.” (ECF No. 27 at 13.) More specifically, 9 Plaintiff cites to a scenario in which a generic settles a patent dispute by agreeing to an early but 10 not immediate entry date with an exclusive license. The generic, Plaintiff claims, will have to 11 prove that such an agreement has generated procompetitive benefits and that the benefits 12 outweigh the anticompetitive effects presumed by the law. (Id.) 13 Again, Plaintiff is not likely to succeed on the merits of this claim. First, Plaintiff cites to 14 no authority holding that the burden of persuasion can never properly be shifted to the defendant 15 to disprove liability, and the Court is aware of none. Indeed, Plaintiff all but concedes that a 16 burden shift in the first instance is not itself a violation of due process. (ECF No. 27 at 9.) 17 Plaintiff’s better argument is that AB 824 does not provide a meaningful opportunity to rebut the 18 presumption because it requires a defendant to show the questioned agreement has already had 19 procompetitive effects. As the law is written, the fact that a settlement supposedly will have 20 procompetitive effects is not sufficient to rebut the antitrust presumption. 21 While seemingly an accurate statement of AB 824’s language, the Court is not convinced 22 that AB 824’s express provision allowing a manufacturer to rebut the presumption by showing 23 procompetitive effects is not meaningful. Here, it is Plaintiff’s burden to establish a likelihood of 24 success on its due process claim. But Plaintiff offers nothing in the way of caselaw or evidence 25 supporting its stance that the process provided for by the statute is not meaningful. First, there are 26 other means of disproving liability, including showing the value received is fair and reasonable 27 compensation solely for other goods or services provided. Also, the parties remain free to invoke 28 any other standard antitrust defense. And moreover, the fact that AB 824 demands a showing that 1 a settlement “has directly generated procompetitive benefits”5 does not render that option 2 meaningless. Indeed, the Court can imagine a scenario where a settlement would have an 3 immediately procompetitive effect. AB 824 simply reflects a desire to penalize parties that enter 4 into agreements that — among other requirements — have not generated procompetitive benefits. 5 To the same point, Plaintiff overstates the changes AB 824 makes to established 6 jurisprudence in the areas of antitrust and patent law. The presumption raised by AB 824 is 7 stronger, and the burden shift may be sharper, but both federal and state antitrust caselaw 8 provides for a similar presumption and burden shift in the context of reverse payment settlement 9 agreements. See FTC v. Actavis, 570 U.S. 136 (2013); In re Cipro Cases I & II, 348 P.3d 845 10 (Cal. 2015). And both federal and state cases make clear that, (1) agreements must be assessed as 11 of the time they are made; and (2) the relevant baseline for determining whether an agreement is 12 procompetitive is the period of competition that would have been, but for the settlement (as 13 opposed to using the life of a valid patent as a baseline). See In re Cipro, 348 P.3d at 158. As set 14 forth in In re Cipro, “Antitrust law condemns the purchase of freedom from competition; what 15 matters is whether a settlement postpones market entry beyond the average point that would have 16 been expected at the time in the absence of agreement.” 348 P.3d at 159. Importantly, AB 824 17 provides a mechanism — indeed more than one — by which a defendant can rebut the 18 presumption arising from a reverse payment settlement. Nothing supports the contention that this 19 mechanism is not meaningful simply because it requires an actual showing of procompetitive 20 benefits as of the time the settlement is entered,6 as opposed to some level of speculation that 21 procompetitive benefits will result at some undetermined time in the future. 22 Finally, Plaintiff asserts AB 824’s presumption that the relevant product market is limited 23 to the branded drug and its generic substitutes renders the anticompetitive presumption 24 5 The State cites to In re Cipro Cases I & II, 348 P.3d 845 at 149–150 (Cal. 2015), to 25 support its contention that this language “draws on established antitrust jurisprudence and the ex ante framework of pay-for-delay jurisprudence.” This “has directly generated” language does not 26 appear in Cipro. 27 6 The Court has no way of knowing how immediate AB 824 enforcement may be after entry 28 of settlement. 1 irrebuttable because it deprives defendants of the opportunity to present every available defense. 2 (ECF No. 10 at 39.) The Court disagrees. AB 824 simply erects a presumption regarding the 3 relevant market. It does not foreclose the defendant from presenting evidence that the relevant 4 market is broader than the one presumed. Granted, AB 824 seems to stack certain presumptions 5 on top of other presumptions. This may have the effect of making it more difficult to rebut all 6 applied presumptions, but nothing indicates to the Court that it has the effect of depriving 7 potential defendants of their due process rights. As a result, the Court finds Plaintiff has not 8 established a likelihood of success on the merits of its due process claim, nor has it raised serious 9 questions going to those merits. Even if Plaintiff had raised serious questions, as discussed 10 below, the balance of hardships does not tip significantly in Plaintiff’s favor such that a 11 preliminary injunction should be granted. 12 B. Irreparable Injury 13 Because the Court finds Plaintiff is not likely at this time to succeed on the merits of any 14 of its claims, it need not address the remaining Winter factors. See Alliance for the Wild Rockies, 15 632 F.3d at 1135 (A plaintiff must “make a showing on all four prongs” of the Winter test to 16 obtain a preliminary injunction.). Nonetheless, the Court briefly discusses the remaining factors, 17 which further support that issuance of a preliminary injunction is not justified at this time. 18 Plaintiff alleges its members will suffer irreparable injury because: (1) AB 824 violates 19 Plaintiff’s members’ constitutional rights and they are therefore per se irreparably injured; (2) 20 they will be forced to make a decision to either continually violate AB 824 and expose 21 themselves to significant liability or litigate every patent dispute to judgment and carry the 22 financial burden of doing so; and (3) as a result of AB 824 and the impossible choice presented 23 by (2), Plaintiff’s members will have no choice but to cease entering the market, leading to lost 24 goodwill and damage to reputation. Moreover, Plaintiff asserts its members will be irreparably 25 harmed by the imposition of a fine pursuant to AB 824 because the Eleventh Amendment 26 prohibits parties from suing state officials, and therefore prevents recoupment of any unjustified 27 payment. In response, the State emphasizes that Plaintiff’s claimed injuries are purely 28 speculative, and that any potential harm to Plaintiff’s members will be the result of their own 1 business choices, not the result of AB 824 itself. The State also argues that because Plaintiff has 2 failed to demonstrate a likelihood of success on the merits of its constitutional claims, it has failed 3 to demonstrate that it will suffer irreparable harm resulting from a constitutional violation. 4 The State is of course correct that absent a likelihood of success on the merits of its 5 constitutional claims, Plaintiff’s claimed per se injury resulting from a constitutional violation 6 necessarily fails. As for Plaintiff’s other claimed injuries, the Court finds Plaintiff overstates the 7 certain and impending harm AB 824 will do. First, AB 824 does not prohibit patent settlements; 8 the claim that AB 824 will force Plaintiff’s members to either violate the law or litigate to 9 judgment, both at great expense, is therefore based on speculation of how companies will choose 10 to react to AB 824’s implementation. But at least one FTC report indicates the majority of patent 11 settlements do not contain a reverse payment at all. (See ECF No. 24 at 19, citing Overview of 12 Agreements Filed in FY 2016, A Report by the FTC Bureau of Competition.) Surely, then, 13 parties to pharmaceutical patent litigation can settle in the aftermath of AB 824. 14 Moreover, “[s]peculative injury does not constitute irreparable injury sufficient to warrant 15 granting a preliminary injunction.” Caribbean Marine Servs. Co. v. Baldrige, 844 F.2d 668, 674 16 (9th Cir. 1988) (citing Goldie's Bookstore, Inc. v. Super. Ct., 739 F.2d 466, 472 (9th Cir.1984)). 17 “A plaintiff must do more than merely allege imminent harm sufficient to establish standing; a 18 plaintiff must demonstrate immediate threatened injury as a prerequisite to preliminary injunctive 19 relief.” Id. (citing Los Angeles Memorial Coliseum Commission v. National Football League, 20 634 F.2d 1197, 1201 (9th Cir.1980)). As discussed above in the context of Plaintiff’s Dormant 21 Commerce Clause claim, nowhere does Plaintiff point to a specific pending case or settlement 22 negotiation in which it will need to act differently as a result of AB 824 (nor is the Court 23 convinced that a change in a drug manufacturer’s business practices would constitute irreparable 24 harm in any event). Speculation of how the market will react to the bill’s implementation is not 25 enough to support a preliminary injunction. 26 Most concerning to the Court is Plaintiff’s claim that any fine improperly levied — 27 especially with respect to an individual — could not be recouped because of the Eleventh 28 Amendment’s protection of state officials. But at this time, that injury is also speculative and not 1 imminent. Indeed, if the State were to pursue a $20 million fine against a minor individual 2 participant in a violative settlement agreement, for example, that individual may be able to state a 3 claim that the law violates the Excessive Fines Clause as applied to them and may be able to seek 4 a preliminary injunction on those grounds. That, however, is not presently before the Court. 5 C. Balance of Hardships and Public Interest 6 The last two factors of the Winter test are: “[] that the balance of equities tips in 7 [plaintiff’s] favor, and [] that an injunction is in the public interest.” Winter, 555 U.S. at 20. 8 “When the government is a party, these last two factors merge.” Drakes Bay Oyster Co. v. 9 Jewell, 747 F.3d 1073, 1092 (9th Cir. 2014). Therefore the Court must analyze the balance 10 between the hardships imposed on AAM and its members and the impact an injunction on the 11 enforcement of AB 824 will have on the public. It is true that there may be some costs and 12 changes to the business practices of Plaintiff’s members as a result of AB 824; however, as 13 discussed above, Plaintiff has failed to establish irreparable injury because its claimed injuries are 14 based purely on speculation as to how members might react to the new law. For the same 15 reasons, the analysis of the burden imposed on Plaintiff therefore does not tip the scale heavily in 16 Plaintiff’s favor. 17 As for the public interest, this factor is at best neutral as both parties argue AB 824 will 18 have the opposite effect. Plaintiff argues that not only does AB 824 impose significant burdens 19 on it and its members, but also that the enforcement of AB 824 is not in the interest of the public. 20 Plaintiff posits that should AB 824 go into effect, generic drug companies will be forced to 21 litigate patent disputes to resolution, significantly increasing litigation costs, decreasing budgets 22 for development of new generic drugs, and thereby decreasing the public’s access to cheaper 23 generic drug alternatives. Plaintiff also foresees generic drug companies refraining from putting 24 any new generics on the market to avoid litigation or liability under AB 824, similarly limiting 25 access to generic alternatives and increasing the cost of prescription drugs on the whole. 26 The State, by contrast, asserts that AB 824 will lower prescription drug prices by closing a 27 loophole in the Hatch-Waxman Act whereby brand-name drug companies are able to preserve 28 otherwise weak patents by paying generic drug companies to keep their drugs off the market. 1 Under the State’s analysis, closing this loophole will ensure that generic and brand companies no 2 longer have an incentive to keep the generic off the market for longer than would be supported by 3 the underlying patent and thus encourage the entry of cheaper generics onto the market faster. 4 According to the State, AB 824 is designed to curb the high costs of prescription drugs. 5 At this juncture, how AB 824 will impact the public interest is purely speculative. The 6 Court cannot predict how the market will react to this new law, nor should it. There is no 7 comparable law in another state nor under federal law, so the Court has no facts before it to base 8 such a determination. Therefore, the balance of equities does not tip in one direction or the other, 9 and it certainly does not tip sharply in Plaintiff’s favor. Thus, this factor does not support the 10 imposition of an injunction against the enforcement of AB 824. 11 VI. CONCLUSION 12 Based on the foregoing, Plaintiff’s Motion for Preliminary Injunction (ECF No. 10) is 13 DENIED. Such denial is without prejudice to Plaintiff seeking another preliminary injunction 14 should certain facts develop and/or certain claims become ripe during the pendency of this 15 litigation. 16 IT IS SO ORDERED. 17 Dated: December 31, 2019 18 19 20 21 22 23 24 25 26 27 28